Yes, that's my take.1. First mover is going to be a huge advantage regardless if another treatment is approved. Any patient showing improvement under Daybue highly unlikely to move unless the side effects are too much2. What if it's priced even higher?
3. I'd hope Medicaid or whatever it's called may cover it
If patients are going to be on it from end of April, pricing would need to get worked out next 2 weeks.
Ann: FDA approves Daybue - the first treatment for Rett syndrome, page-66
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |